Acute myeloid leukemia (AML) is a heterogeneous group of diseases characterized by
uncontrolled proliferation of hematopoietic stem cells in the bone marrow. Malignant cell …

Activation of Mechanistic target of rapamycin (mTOR) signaling plays a crucial role in
tumorigenesis of numerous malignancies including glioblastoma (GB). The Canonical …

The importance of the physiological function of phosphatase and tensin homologue (PTEN)
is illustrated by its frequent disruption in cancer. By suppressing the phosphoinositide 3 …

In mammals, the insulin receptor (IR) gene has acquired an additional exon, exon 11. This
exon may be skipped in a developmental and tissue-specific manner. The IR, therefore …

We present an individualized systems medicine (ISM) approach to optimize cancer drug
therapies one patient at a time. ISM is based on (i) molecular profiling and ex vivo drug …

Numerous studies have established a causal link between aberrant mammalian target of
rapamycin (mTOR) activation and tumorigenesis, indicating that mTOR inhibition may have …

The tumor suppressor PTEN was originally identified as a negative regulator of the
phosphoinositide 3-kinase (PI3K) signaling, a main regulator of cell growth, metabolism and …

Therapeutic targeting of integral biological pathways, including those involving vascular
endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR), has …

Acute myeloid leukemia (AML) is a highly heterogeneous hematopoietic malignancy
characterized by excessive proliferation and accumulation of immature myeloid blasts in the …

Cancer cells require nutrients and energy to adapt to increased biosynthetic activity, and
protein synthesis inhibition downstream of mammalian target of rapamycin complex 1 …